Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.

This document discusses the emerging safety issue of ocrelizumab-associated enteritis in patients with multiple sclerosis (MS). It presents a case study and reviews existing literature on enteritis in MS patients receiving ocrelizumab. The authors propose the term "Ocrelizumab-Associated Enteritis" to encompass these digestive tract manifestations. The document also provides a list of case studies involving MS patients who experienced gastrointestinal symptoms, including diarrhea, bloody diarrhea, lower abdominal pain, and fever. The underlying gastrointestinal conditions identified in these cases include ulcerative pancolitis, Crohn's disease, diverticulitis, and terminal ileitis. The management of Ocrelizumab-Associated Colitis (OAC) is still being studied, and further research is needed to better understand and manage this condition. [Extracted from the article]